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ABSTRACT 21 
Isolation of non-tuberculous mycobacteria (NTM) from the sputum of patients with cystic 22 
fibrosis (CF) is challenging due to overgrowth by rapidly-growing species that colonise the 23 
lungs of patients with CF. Extended incubation of Burkholderia cepacia selective agar 24 
(BCSA) has been recommended as an expedient culture method for isolation of rapidly-25 
growing NTM in this setting. The aim of this study was to assess the efficacy of five selective 26 
media designed for the isolation of Burkholderia cepacia complex (BCC) along with two 27 
media designed for the isolation of mycobacteria (RGM medium and Middlebrook 7H11 28 
agar) for their ability to isolate NTM. All seven media were challenged with 147 isolates of 29 
rapidly-growing mycobacteria and 185 isolates belonging to other species. RGM medium 30 
was then compared with the most selective brand of BCSA for the isolation of NTM from 31 
224 sputum samples from patients with CF. Different agars designed for isolation of B. 32 
cepacia complex varied considerably in their inhibition of other bacteria and fungi. RGM 33 
medium supported the growth of all isolates of mycobacteria and was more selective than any 34 
other medium. NTM were recovered from 17 of 224 sputum samples using RGM medium 35 
compared with only seven samples using the most selective brand of BCSA (P = 0.023). 36 
RGM medium offers a superior option to other selective agars for isolation of rapidly-37 
growing mycobacteria from the sputum of patients with CF. Furthermore, the convenience of 38 
using RGM medium enables routine screening for rapidly-growing NTM in all sputum 39 
samples submitted by patients with CF. 40 
 41 
 42 
 43 
 44 
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IINTRODUCTION 45 
Burkholderia cepacia complex (BCC) and non-tuberculous mycobacteria (NTM) are both 46 
recognized as potentially important pathogens when isolated from the lungs of patients with 47 
cystic fibrosis (CF). The use of a selective culture medium is recommended for isolation of 48 
BCC (1) and several brands of such media are commercially available. Rapidly-growing 49 
mycobacteria represent a subset of NTM that generate colonies on solid culture media within 50 
seven days of incubation (2). The predominant species of NTM within the CF population in 51 
Europe is Mycobacterium abscessus complex (MABSC) (3-5) and there is convincing 52 
evidence that the prevalence of infection by MABSC is increasing in the CF population (3, 5-53 
7). This rapidly-growing species comprises three subspecies: Mycobacterium abscessus 54 
subsp. abscessus, Mycobacterium abscessus subsp. bolletii and Mycobacterium abscessus 55 
subsp. massiliense.  56 
Culture of mycobacteria from sputum samples traditionally relies upon methods that 57 
were designed to accommodate slow growing mycobacteria – in particular Mycobacterium 58 
tuberculosis, which is comparatively rare in cystic fibrosis patients. Such methods are 59 
laborious and expensive as they involve chemical decontamination of samples and 60 
subsequent culture on both liquid and solid media (8, 9). Furthermore, contamination of 61 
cultures by faster-growing microorganisms may mean that cultures have to be abandoned (9), 62 
and decontamination protocols may reduce the yield of mycobacteria (8).  63 
Esther et al. (2011) demonstrated that extended incubation of Burkholderia cepacia 64 
selective agar (BCSA) afforded an increased recovery rate of NTM from 0.7% to 2.8% using 65 
routine microbiological culture methods and recommended this as an expedient method for 66 
culture of rapidly-growing mycobacteria from patients with CF (10). The aim of this study 67 
was to assess five commercially-available media designed for the isolation of BCC for their 68 
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ability to support the growth of BCC (n = 43) and rapidly-growing mycobacteria (n = 147). 69 
We also assessed the selectivity of these culture media against 142 other bacteria and fungi, 70 
focussing on the inclusion of species frequently recovered from the sputum of patients with 71 
CF. Two agar-based media designed for the isolation of mycobacteria (RGM medium and 72 
Middlebrook 7H11 agar) were included for comparison. The two media with the most 73 
potential to recover mycobacteria were compared for their ability to isolate rapidly-growing 74 
NTM from 224 sputum samples from patients with CF. 75 
MATERIALS AND METHODS 76 
Materials. All five media for isolation of BCC were purchased as pre-poured plates from 77 
their respective manufacturers. Burkholderia cepacia selective agar (BCSA; Product Ref: 78 
33631) and Cepacia selective agar (Product Ref: 44347) were purchased from bioMérieux, 79 
Basingstoke, UK or bioMérieux, Nürtingen, Germany. Burkholderia cepacia agar (Product 80 
Ref: PO0938) was purchased from Oxoid Ltd, Basingstoke, UK. BD Cepacia medium 81 
(Product Ref: 256180) and BD OFPBL (oxidation-fermentation polymyxin-bacitracin-82 
lactose) medium (Product Ref: 254481) were purchased from BD Diagnostic Systems, 83 
Oxford, UK. Middlebrook 7H11 agar (Product Ref: PP4080) was obtained from E&O 84 
Laboratories, Bonnybridge, UK, as pre-poured plates. Blood agar was prepared from 85 
Columbia agar powder (Oxoid, Basingstoke, UK) and supplemented with 5% defibrinated 86 
horse blood (TSC Biosciences, Buckingham, UK). Sabouraud agar and bacteriological agar 87 
were purchased from Oxoid, Basingstoke, UK. A sample of 9-chloro-9-[4-88 
(diethylamino)phenyl]-9,10-dihydro-10-phenylacridine hydrochloride (C-390) was kindly 89 
synthesized by Dr. Annette Johnston of Northumbria University, Newcastle upon Tyne, UK 90 
but is also available commercially from Biosynth, Staad, Switzerland. Colistin 91 
methanesulfonate, yeast extract and amphotericin B were kindly provided by bioMérieux, 92 
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Craponne, France. All other chemicals and antibiotics were purchased from Sigma-Aldrich, 93 
Poole, UK. 94 
Preparation of RGM medium. RGM (rapidly-growing mycobacteria) medium was 95 
designed and prepared by staff at the Freeman Hospital Microbiology Department (Newcastle 96 
upon Tyne, UK) and is an adaptation of Middlebrook agar described by Middlebrook and 97 
Cohn in 1958 (11). A tenfold-strength solution of Middlebrook 7H9 broth was prepared by 98 
dissolving the following ingredients in 960 ml of deionized water: ammonium sulphate (5 g), 99 
L-glutamic acid (5 g), di-sodium phosphate (25 g), mono-potassium phosphate (10 g), 100 
sodium citrate (1 g), magnesium sulfate (0.5 g), calcium chloride (0.005 g), biotin (0.005 g), 101 
copper sulfate (0.01 g), zinc sulfate (0.01 g), pyridoxine (0.01 g), ferric ammonium citrate 102 
(0.4 g) and 40 ml of glycerol. The pH of the solution was adjusted to 6.6 and it was sterilized 103 
by autoclaving at 116°C for 20 minutes. One hundred milliliters of this solution was added to 104 
750 ml of deionized water with 10 g of agar and 4 g of yeast extract and this was autoclaved 105 
as before and allowed to cool to 50°C in a waterbath. OADC supplement was prepared by 106 
dissolving 5 g bovine serum albumin, 2 g glucose, 0.004 g catalase and 63 µl oleic acid in 107 
100 ml deionized water. The OADC supplement was filter sterilized and added to the molten 108 
agar. Finally, the following additives were each dissolved in 10 ml sterile deionized water 109 
and added to make 1 liter of medium: 32 mg colistin (as colistin methanesulfonate), 400 mg 110 
fosfomycin, 25 mg glucose-6-phosphate, 5 mg amphotericin and 32 mg C-390. Amphotericin 111 
required initial dissolution in 200 µl of N-methyl-2-pyrrolidinone followed by addition of 9.8 112 
ml sterile deionized water. The agar was immediately poured into 90 mm Petri dishes. 113 
 114 
Microbial strains. A collection of 147 isolates of rapidly-growing mycobacteria 115 
previously isolated by standard methods from sputum samples from patients with CF was 116 
used for evaluation of all media. These included Mycobacterium abscessus subsp. abscessus 117 
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(n = 79), Myobacterium chelonae (n = 43), Mycobacterium abscessus subsp. massiliense (n = 118 
12), Mycobacterium abscessus subsp. bolletii (n = 3), Mycobacterium fortuitum (n = 3), 119 
Mycobacterium salmoniphilum (n = 3), Mycobacterium llatzerense (n = 2), Mycobacterium 120 
immunogenum (n = 1) and Mycobacterium mucogenicum (n = 1). Seventy three of these 121 
isolates were obtained from the Microbiology Department, Freeman Hospital, Newcastle 122 
upon Tyne, UK and all were from distinct patients. Seventeen were kindly provided by St. 123 
Vincent's University Hospital, Dublin, Ireland and were also from distinct patients. The 124 
remaining 57 were consecutive clinical isolates kindly supplied by Public Health England, 125 
Newcastle upon Tyne, UK. The species and subspecies identity of all strains had been 126 
previously confirmed by sequencing of at least two of three housekeeping genes (rpoB, hsp65 127 
and sodA) as previously described (12). 128 
 129 
The collection of non-mycobacteria was selected to represent a variety of species 130 
frequently recovered from the sputa of patients with CF. Non-mycobacterial strains (n = 185) 131 
were obtained from national culture collections (n = 23) or from the culture collection of the 132 
Microbiology Department, Freeman Hospital, Newcastle upon Tyne (n = 162) and included 133 
an international Pseudomonas aeruginosa reference panel (n = 43) (13) and a BCC 134 
experimental strain panel (n = 26) (14-16) as well as clinical isolates of both species. In total, 135 
the collection comprised: Pseudomonas aeruginosa (n = 55), BCC (n = 43), Staphylococcus 136 
aureus (n = 28), various species of Enterobacteriaceae (n = 11), Achromobacter 137 
xylosoxidans (n = 8), Ralstonia mannitolilytica (n = 7), Stenotrophomonas maltophilia (n = 138 
4), Streptococcus spp. (n = 4), Aspergillus spp. (n = 3), Candida spp. (n = 3), Pandoraea spp. 139 
(n = 3), Acinetobacter spp. (n = 2), Enterococcus spp. (n = 2), Inquilinus limosus (n = 2), 140 
Scedosporium spp. (n = 2), Bacillus subtilis (n = 1), Delftia acidovorans (n = 1), 141 
 on D
ecem
ber 13, 2018 by guest
http://jcm
.asm
.org/
D
ow
nloaded from
 
7 
 
Elizabethkingia miricola (n = 1), Geosmithia argillacea (n = 1), Haemophilus influenzae (n = 142 
1), Moraxella catarrhalis (n = 1), Neisseria flavescens (n = 1) and Ochrobactrum sp. (n = 1).  143 
 144 
Inoculation of isolates onto culture media. Strains were previously stored at -20oC 145 
in glycerol/skimmed milk and frozen isolates were subcultured onto Columbia agar with 5% 146 
horse blood prior to testing. Each isolate was suspended in 1 ml of saline (0.85%) to a 147 
turbidity equivalent to a McFarland 0.5 standard (approximately 1.5 × 108 CFU/ml) using a 148 
densitometer. For NTM rough colony-types, where clumping occurred, vortexing with three 149 
sterile 3 mm glass beads for 10 min effectively dispersed all clumps. A 1 μl aliquot of each 150 
suspension of mycobacteria was inoculated onto each medium type and the inoculum was 151 
spread using a loop. Filamentous fungi were inoculated in the same way. Suspensions of all 152 
other isolates were inoculated onto media using a multipoint inoculator to deliver inocula of 153 
approximately 1 μl per spot (i.e. approximately 1.5 × 105 CFU/spot). All plates were 154 
incubated at 30°C and growth was recorded after four, seven days and ten days of incubation. 155 
To demonstrate the viability of isolates, Columbia blood agar for bacterial isolates and 156 
Sabouraud agar for fungal isolates were used as controls. All tests were performed in 157 
duplicate on separate occasions. 158 
 159 
Comparison of RGM medium with BCSA (Ref: 33631) for isolation of 160 
mycobacteria from sputum samples. From the data generated in the experiments detailed 161 
above, the most selective brand of BCSA (Ref: 33631) was evaluated against RGM medium 162 
for isolation of mycobacteria from sputum samples. A total of 224 consecutive sputum 163 
samples were prospectively collected from 133 adults and children with CF attending the 164 
Christiane Herzog CF-Centre, University Hospital Frankfurt, Frankfurt am Main, Germany, 165 
between July 2015 and January 2016. Samples were digested using Copan Sputum 166 
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Liquefying solution in accordance with manufacturer’s instructions. After vortexing for 30 s 167 
samples were left for 15 minutes. A 100 µL aliquot was then cultured onto RGM and BCSA 168 
(bioMérieux Ref: 33631) and the inoculum was spread to obtain isolated colonies. Both 169 
media were incubated for 10 days at 30°C and examined for growth after 4, 7 and 10 days of 170 
incubation. A minority of samples were read after 11-12 days of incubation if the day of the 171 
final reading fell on a weekend. 172 
  Colonies were identified by matrix-assisted laser desorption/ionization time-of-flight 173 
mass spectrometry using VITEK-MS IVD system with knowledge database version 2.0 174 
(bioMérieux, Nürtingen, Germany). Suspected isolates of mycobacteria were confirmed as 175 
acid-fast bacilli using a Ziehl-Neelsen stain and identified to species level by sequencing of 176 
the internal transcribed spacer (ITS) region. The ITS region was amplified with primers ITS1 177 
5’-GATTGGGACGAAGTCGTAAC-3’ and ITS2 5’-AGCCTGCCACGTCCTTCATC-3’ 178 
(TIB MOLBIOL, Berlin, Germany) as previously described (17). PCR was performed in a 50 179 
μl reaction mixture with 0.4 pmol/µl of each primer, 1.5 mM MgCl2, 0.2 mM of dATP, 180 
dGTP, dCTP, dTTP (Roche, Mannheim, Germany), 1.25 U of Taq polymerase (Invitrogen, 181 
Darmstadt, Germany) and an annealing temperature of 64°C for 40 cycles. The PCR product 182 
was sequenced in both directions using ITS1 and ITS2 and the resulting DNA sequence was 183 
aligned with NCBI sequence database.  184 
 185 
Statistical analysis. Any difference in performance of the two media for isolation of 186 
NTM from sputum samples was investigated for statistical significance using McNemar's test 187 
with the continuity correction applied. Statistical significance was assigned to a probability 188 
(P) value of ≤ 0.05. 189 
 190 
 191 
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RESULTS 192 
Evaluation of seven selective agars for supporting the growth of mycobacteria. Clear 193 
differences were revealed between the five different brands of BCSA in terms of their ability 194 
to support the growth of mycobacteria. For example, on Cepacia selective agar (bioMérieux) 195 
95.9% of mycobacteria generated growth within 4 days of incubation compared with only 196 
40.1% of isolates on Oxoid B. cepacia agar (Table 1). After 10 days of incubation, ten 197 
isolates had still not grown on Oxoid B. cepacia agar including MABSC (n = 4), M. chelonae 198 
(n = 3), M. llatzerense (n = 2) and M. mucogenicum (n = 1). All isolates were recovered on 199 
Cepacia selective agar (bioMérieux; Ref: 44347) whereas other selective agars for BCC 200 
failed to support the growth of between four and eight isolates. All isolates were recovered on 201 
Middlebrook 7H11 agar and RGM medium. 202 
 203 
Evaluation of seven selective agars for inhibition of non-mycobacteria. Table 2 204 
provides insights into the selectivity of the seven selective media with 185 non-mycobacteria. 205 
All five media for BCC showed effective inhibition of P. aeruginosa, which is an essential 206 
attribute of such media. Inhibition of other species was more variable however. For example, 207 
of 28 isolates of S. aureus (mainly methicillin-resistant strains), 21 (75%) were able to grow 208 
on BD OFPBL medium whereas only three isolates were able to grow on Oxoid B. cepacia 209 
agar and bioMérieux BCSA (Ref: 33631). All brands of media for isolation of BCC showed a 210 
poor ability to inhibit the growth of fungi – particularly Aspergillus spp. and yeasts. Overall, 211 
bioMérieux BCSA showed the greatest selectivity and BD OFPBL showed the weakest 212 
selectivity against non-mycobacteria among the five brands tested.  213 
 214 
Although Middlebrook selective medium is designed specifically for the isolation of 215 
mycobacteria from clinical samples, growth of non-mycobacterial species was common with 216 
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75 out of 186 (40.3%) isolates able to grow. Overall, its selectivity was inferior to the two 217 
most selective media for BCC, although it was able to inhibit the growth of Aspergillus 218 
fumigatus. RGM medium was by far the most selective of all of the agars tested, with 90% of 219 
non-mycobacteria inhibited including all fungi and Gram-positive bacteria (Table 2). 220 
 221 
Performance of selective agars for supporting growth of BCC. Of the five brands 222 
of media for BCC, none was able to support the growth of every isolate of BCC within the 223 
standard incubation period of 5 days (Table 3). Cepacia selective agar (bioMérieux; 44347) 224 
showed the highest sensitivity (93%) with only three isolates inhibited (1 B. stabilis and 2 B. 225 
multivorans) whereas the growth of seven isolates was inhibited on Oxoid B. cepacia agar (B. 226 
cenocepacia (n = 1), B. multivorans (n = 5), B. stabilis (n = 1)). Extended incubation up to 227 
ten days resulted in three additional isolates recovered on BD OFPBL medium but had no 228 
impact on other brands of BCSA. 229 
 230 
Comparison of RGM medium with BCSA (Ref: 33631) for recovery of 231 
mycobacteria from sputum samples. A total of 17 isolates of mycobacteria were recovered 232 
from 224 sputum samples (Table 4). These 17 isolates were derived from a total of 12 233 
patients (prevalence: 12/133; 9%). For four of these 12 patients, the same species was 234 
recovered from more than one sample. 235 
 236 
All 17 isolates of mycobacteria were recovered on RGM medium compared with only 237 
seven (41%) recovered on BCSA (P = 0.023). For seven of 12 patients, mycobacteria were 238 
only detected using RGM medium (P = 0.023). The calculation of sensitivity in Table 4 is for 239 
comparative purposes only and assumes that all mycobacteria were recovered by at least one 240 
of the two methods. Clearly this cannot be proven and moreover might be considered 241 
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unlikely for slower-growing species such as M. avium complex. The average time-to-242 
detection for mycobacteria was 7.9 days using RGM medium (range 4-11 days) and 7 days 243 
using BCSA (range 4-11 days). 244 
 245 
Table 4 shows that RGM medium was much more selective than BCSA for the 246 
inhibition of non-mycobacteria with only 17 isolates of non-mycobacteria recovered on RGM 247 
medium from 224 sputum samples (compared with 59 on BCSA). This is highly likely to 248 
have had an impact on the recovery of mycobacteria on BCSA. For example, for the ten 249 
sputum samples shown to contain mycobacteria that were not recovered on BCSA, five of 250 
these showed growth of other bacterial species (n = 3) or fungal species (n = 2) on BCSA. All 251 
17 isolates of mycobacteria recovered on RGM medium were isolated in pure culture. 252 
 253 
DISCUSSION 254 
 255 
The accurate and prompt detection of rapidly-growing NTM for patients with CF is important 256 
for treatment management and for infection control purposes. In the only previously reported 257 
study with RGM medium, a comparison was performed with Cepacia selective agar 258 
(bioMérieux; 44347) for the isolation of mycobacteria from 502 sputum samples. 259 
Mycobacteria were detected in 54 samples using RGM medium and from only 17 samples 260 
using Cepacia selective agar (P ≤ 0.0001) (18). As media for isolation of B. cepacia have 261 
been recommended for isolation of mycobacteria, this prompted us to examine different 262 
commercial brands of such media to compare their ability to support the growth of rapidly-263 
growing mycobacteria and their selectivity against other flora associated with CF sputum 264 
samples. Cepacia selective agar (bioMérieux; 44347) was at least as effective for the recovery 265 
of pure strains of mycobacteria as any other selective agar for B. cepacia. It was less selective 266 
 on D
ecem
ber 13, 2018 by guest
http://jcm
.asm
.org/
D
ow
nloaded from
 
12 
 
than some other agars and much of this could be attributed to lack of inhibition of methicillin-267 
resistant S. aureus. Cepacia selective agar was less selective than bioMérieux BSCA but 268 
more selective than BD OFPBL. 269 
 270 
In 1985, Gilligan et al. were the first to report the design of a selective culture 271 
medium for B. cepacia (PC medium) for use with sputum samples from patients with CF 272 
(19). Their medium included polymyxin B, ticarcillin, crystal violet and bile salts as selective 273 
agents and such agents are commonly exploited in commercial brands. At around the same 274 
time, Welch et al. evaluated the use of OFPBL medium, exploiting the use of polymyxin B 275 
and bacitracin as selective agents (20). Finally, in 1997, Henry et al. described B. cepacia 276 
selective agar (BCSA) and showed it to have greater selectivity than PC agar and OFPBL 277 
medium. In this medium, polymyxin B and crystal violet were retained as selective agents 278 
with the addition of gentamicin and vancomycin (21). In a large trial with 656 clinical 279 
samples, Henry et al. concluded that BCSA was superior to OFPBL and PC medium for 280 
supporting the growth of B. cepacia and suppressing the growth of other flora (22). In this 281 
study we re-affirm the high selectivity of BCSA, which was much more selective than 282 
OFPBL, however, six isolates of BCC were inhibited using BCSA. The selective agents 283 
exploited by various pre-poured media commercially available for isolation of BCC are 284 
detailed in Table 5.  285 
 286 
Mycobacteria grow more slowly than most if not all of the other bacterial and fungal 287 
isolates commonly recovered from sputum samples from patients with CF; this means that 288 
high selectivity is extremely important to inhibit or restrict the growth of non-mycobacteria 289 
so that they do not remain undetected due to overgrowth by other species. Although BCSA 290 
was the most selective of the agars designed for recovery of BCC, it was much less selective 291 
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than RGM medium. If BCC is excluded (as BCSA is designed to detect this species), 25 non-292 
mycobacteria were able to grow on BCSA compared with only six on RGM medium (Table 293 
1). A particular drawback of selective agars for BCC is their failure to inhibit fungi, and 294 
particularly Aspergillus species. On extended incubation of these media, the growth of 295 
Aspergillus can overwhelm the entire culture plate severely compromising the isolation of 296 
mycobacteria. This is particularly problematic with sputum samples from CF patients where 297 
infection of mycobacteria has been associated with concomitant isolation of Aspergillus sp. 298 
(23, 24).  299 
 300 
Middlebrook 7H11 agar, designed for isolation of mycobacteria, was better at 301 
inhibiting fungi, due to the inclusion of amphotericin (Table 5). However, other species, such 302 
as Aspergillus terreus and Scedosporium apiospermum remained uninhibited and overall the 303 
selectivity of Middlebrook 7H11 agar was inferior to that of bioMérieux BCSA and Oxoid B. 304 
cepacia agar (Table 1). In contrast, no yeasts or fungi were able to grow on RGM medium.  305 
 306 
As BCSA (Ref: 33631) was found to the most selective of the five media designed for 307 
isolation of BCC (and more selective than Middlebrook 7H11 agar), it was compared with 308 
RGM for further evaluation with 224 sputum samples. The study with sputum samples 309 
confirmed the superior selectivity of RGM medium (Table 4) and it is likely that this 310 
facilitated the significantly greater yield of mycobacteria recovered on RGM medium (P = 311 
0.023). We believe that the use of RGM medium constitutes a simple, convenient method for 312 
culture of mycobacteria that can be embedded within routine diagnostic methods allowing the 313 
culture of all submitted sputum samples from patients with CF. A dedicated culture method 314 
for detection of BCC is accepted practice for sputum samples from patients with CF (1) and it 315 
is noteworthy that NTM were recovered in almost three times as many samples as BCC in 316 
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this study. From our analysis we conclude that RGM medium offers a superior option 317 
compared with any of the other selective agars for screening and monitoring of rapidly-318 
growing mycobacteria from the sputum of patients with CF. Further studies are required to 319 
compare the sensitivity of RGM medium with formal culture methods for acid-fast bacilli 320 
(AFB), (e.g. automated liquid culture). It would also be of interest to examine the utility of 321 
RGM medium in locations where slower-growing species of mycobacteria, such as M. avium 322 
complex, may predominate. Until such data are available, formal AFB culture methods 323 
remain essential in order to detect slow-growing species of NTM (25). 324 
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TABLE 1 Percentage of rapidly-growing mycobacteria recovered on various selective agars at 
30°C. 
  n 
BCSA 
Cepacia 
selective 
agar 
B. 
cepacia 
agar 
Cepacia 
medium OFPBL 
RGM 
medium 
Middlebrook 
7H11 agar 
bioMérieux bioMérieux Oxoid BD BD - E&O Laboratories 
33631 44347 PO0938 256180 254481  - PP4080 
MABSC 94 
Day 4 92.6 96.8 57.4 96.8 93.6 98.9 98.9 
Day 7 98.9 98.9 91.5 98.9 98.9 98.9 98.9 
Day 10 98.9 100 95.7 100 98.9 100 100 
M. chelonae 43 
Day 4 97.7 100 9.3 95.3 100 100 100 
Day 7 100 100 69.8 95.3 100 100 100 
Day 10 100 100 93 97.7 100 100 100 
Other species 10 
Day 4 10 70 10 70 40 90 70 
Day 7 30 80 60 70 40 90 70 
Day 10 30 100 70 70 70 100 100 
Total 
mycobacteria 147 
Day 4 88.4 95.9 40.1 94.6 91.8 98.6 97.3 
Day 7 94.6 98 83 95.9 95.2 98.6 97.3 
Day 10 94.6 100 93.2 97.3 97.3 100 100 
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TABLE 2 Number of non-mycobacteria isolates recovered on various selective agars after 10 
days of incubation at 30°C. 
  n 
BCSA 
Cepacia 
selective 
agar 
B. 
cepacia 
agar 
Cepacia 
medium OFPBL 
RGM 
medium 
Middlebrook 
7H11 agar 
bioMérieux bioMérieux Oxoid BD BD - E&O Laboratories 
33631 44347 PO0938 256180 254481 - PP4080 
     
Gram Negatives 141 54 60 55 59 72 18 63 
Enterobacteriaceae 11 2 0 2 2 6 0 1 
A. xylosoxidans 8 3 3 3 5 8 2 3 
Acinetobacter sp. 2 0 0 0 0 0 0 0 
B. cepacia 
complex 43 37 40 36 37 41 12 39 
D. acidovorans 1 1 0 0 0 1 0 0 
E. miricola 1 1 1 1 0 1 0 1 
H. influenzae  1 0 0 0 0 0 0 0 
I. limosus 2 0 2 0 2 0 1 2 
M. catarrhalis 1 0 0 0 0 0 0 0 
Neisseria 
flavescens 1 1 1 1 1 1 1 1 
Ochrobactrum sp. 1 0 1 1 1 1 0 1 
P. aeruginosa 55 0 2 1 2 2 0 2 
Pandoraea spp. 3 3 3 3 3 3 2 3 
R. mannitolilytica 7 6 6 6 6 5 0 7 
S. maltophilia 4 0 1 1 0 3 0 3 
Gram Positives 35 3 11 3 14 21 0 7 
B. subtilis 1 0 0 0 0 0 0 0 
Enterococcus spp. 2 0 0 0 0 0 0 0 
S. aureus 28 3 11 3 14 21 0 7 
Streptococcus spp. 4 0 0 0 0 0 0 0 
Yeast and Fungi 9 5 8 9 8 8 0 3 
A. fumigatus 2 2 2 2 2 2 0 0 
A. terreus 1 1 1 1 1 1 0 1 
Candida spp. 3 2 3 3 3 3 0 1 
G. argillacea 1 0 0 1 0 0 0 0 
S. apiospermum 1 0 1 1 1 1 0 1 
S. prolificans 1 0 1 1 1 1 0 0 
Total 185 62 79 67 81 101 18 73 
Total excluding     
B. cepacia 
complex 
142 25 39 31 44 60 6 34 
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TABLE 3 No. of isolates of B. cepacia complex recovered on various selective agars after 5 
days of incubation at 30°C. 
  n 
BCSA 
Cepacia 
selective 
agar 
B. 
cepacia 
agar 
Cepacia 
medium OFPBL 
RGM 
medium 
Middlebrook 
7H11 agar 
bioMérieux bioMérieux Oxoid BD BD - E&O Laboratories 
33631 44347 PO0938 256180 254481 - PP4080 
B. ambifaria 2 1 2 2 2 1 0 0 
B. anthina 2 1 2 2 1 1 0 1 
B. cenocepacia 11 11 11 10 9 10 3 11 
B. cepacia 3 3 3 3 3 3 0 3 
B. contaminans  1 1 1 1 1 1 0 1 
B. dolosa 2 2 2 2 2 2 0 1 
B. multivorans 12 10 10 7 10 11 2 10 
B. pyrrocinia 2 2 2 2 2 2 1 1 
B. stabilis 4 2 3 3 3 3 0 3 
B. vietnamiensis 4 4 4 4 4 4 0 4 
Total 43 37 40 36 37 38 6 35 
% recovery 86 93 84 86 88 14 81 
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TABLE 4 Numbers of isolates of mycobacteria and other species recovered  
on BSCA and RGM medium from culture of 224 sputum samples. 
    
RGM BCSA (Ref: 33631) 
Total mycobacteria 17 7 
M. abscessus complexa 9 6 
M. avium complex 1 0 
M. chelonae 1 0 
M. mucogenicum 2 0 
M. simiae 3 1 
Mycobacterium species 1 0 
Sensitivity (%) 100 41 
Total non-mycobacteria 17 59 
Achromobacter sp. 6 13 
Burkholderia multivorans 5 7 
Chryseobacterium sp. 0 1 
Cupriavidus sp. 1 1 
Proteus mirabilis 0 4 
Pseudomonas aeruginosa 0 7 
Serratia marcescens 0 2 
Sphingobacterium spiritivorum 0 1 
Stenotrophomonas maltophilia 0 2 
Aspergillus fumigatus 2 9 
Aspergillus terreus 0 1 
Candida spp. 1 7 
Exophiala dermatitidis 0 1 
Geotrichum sp. 1 1 
Trichosporon mycotoxinivorans 1 1 
Unidentified fungus 0 1 
No growth 190 160 
 
  
aSub-speciation of the M. abscessus complex was not possible using  458 
the ITS sequencing method used for identification in Frankfurt. 459 
 460 
 461 
 462 
 463 
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TABLE 5 Selective agents (per liter) included in various culture media as disclosed  
by manufacturers a 
  
BCSA 
Cepacia 
selective 
agar 
B. 
cepacia 
agar 
Cepacia 
medium OFPBL 
RGM 
medium 
Middlebrook 
7H11 agar b 
bioMérieux bioMérieux Oxoid BD BD - E&O Laboratories 
33631 44347 PO0938 256180 254481 - PP4080 
Polmyxyn B 600000 U 300 000 U 150000 U 300000 U 300000 U  - Included 
Colistin  -  -  -  -  - 32 mg  - 
Crystal violet 2 mg 1 mg 1 mg 1 mg  -  - - 
Bile salts  - 0.5 g 1.5 g 0.5 g  -  - - 
Ticarcillin  - 10 mg 100 mg 100 mg  -  - Included 
Gentamicin 10 mg  - 5 mg  -  -  - - 
Vancomycin 2.5 mg  -  -  -  -  - - 
Bacitracin   -  -  -  - 200 U  -  - 
Trimethoprim  -  -  -  -  -  - Included 
Amphotericin B  -  -  -  -  - 5 mg Included 
Malachite Green  -  -  -  -  -  - Included 
Fosfomycin  -  -  -  -  - 0.4 g  - 
C-390  -  -  -  -  - 32 mg  - 
                
a The composition of these media may be adjusted by manufacturers to meet performance requirements. 465 
b Concentrations are not published for selective agents in E&O Middlebrook 7H11 agar. 466 
 467 
 468 
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